Trexquant Investment LP Black Diamond Therapeutics, Inc. Transaction History
Trexquant Investment LP
- $7.59 Billion
- Q3 2024
A detailed history of Trexquant Investment LP transactions in Black Diamond Therapeutics, Inc. stock. As of the latest transaction made, Trexquant Investment LP holds 135,868 shares of BDTX stock, worth $372,278. This represents 0.01% of its overall portfolio holdings.
Number of Shares
135,868Holding current value
$372,278% of portfolio
0.01%Shares
7 transactions
Others Institutions Holding BDTX
# of Institutions
114Shares Held
48.8MCall Options Held
1.8MPut Options Held
1.86M-
T. Rowe Price Investment Management, Inc. Baltimore, MD10.7MShares$29.4 Million0.03% of portfolio
-
Bellevue Group Ag Kuesnacht, V88.52MShares$23.3 Million0.62% of portfolio
-
Vestal Point Capital, LP New York, NY5.03MShares$13.8 Million1.66% of portfolio
-
Nea Management Company, LLC Timonium, MD4.45MShares$12.2 Million1.48% of portfolio
-
Black Rock Inc. New York, NY3.22MShares$8.81 Million0.0% of portfolio
About Black Diamond Therapeutics, Inc.
- Ticker BDTX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 36,339,500
- Market Cap $99.6M
- Description
- Black Diamond Therapeutics, Inc., a biotechnology company, discover, develops, and commercializes medicines for patient with genetically defined tumors. It develops BDTX-189, an irreversible small molecule inhibitor that is designed to targets oncogenic proteins defined by the non-canonical epidermal growth factor receptor (EGFR) and human epide...